sanofi logo
regeneron logo

Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014

- Alirocumab, an investigational treatment for hypercholesterolemia, showed a 62 percent reduction in LDL-C compared to placebo at 24 weeks on top of maximally-tolerated lipid-lowering therapy in ODYSSEY LONG TERM trial -

/ PR Newswire / — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). Results from the four ongoing trials, all of which met their primary efficacy endpoint, will be presented today at a Hot Line session at the ESC Congress 2014 in Barcelona, Spain.
Read More

“Across these four trials, alirocumab showed significant and sustained reductions in LDL-C over one year on top of standard-of-care statin therapy across different patient types,” said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. “We are also encouraged by the consistent safety profile across the trials, including in ODYSSEY LONG TERM, the largest Phase 3 trial of a PCSK9 inhibitor, with the longest follow-up period reported to date.”

Click here to read the full release.

Embed Code
x
<iframe id='inlineFrameId' name='inlineframe' src="http://www.multivu.com/players/English/7298631-sanofi-regeneron-pharmaceuticals-announce-positive-results-alirocumab-trials-at-esc-congress/embed.html" frameborder="0" scrolling="no" width="512" height="384" marginwidth="0" marginheight="0" ></iframe>
<OBJECT id="impID3e9509df-4f60-4dad-8fc6-d7903157fab7" type="application/x-shockwave-flash" data="http://www.multivu.com/players/English/7298631-sanofi-regeneron-pharmaceuticals-announce-positive-results-alirocumab-trials-at-esc-congress/flexSwf/3e9509df-4f60-4dad-8fc6-d7903157fab7.512x384.swf" width="512" height="384"><PARAM NAME="movie" VALUE="http://www.multivu.com/players/English/7298631-sanofi-regeneron-pharmaceuticals-announce-positive-results-alirocumab-trials-at-esc-congress/flexSwf/3e9509df-4f60-4dad-8fc6-d7903157fab7.512x384.swf"><PARAM NAME="quality" VALUE=high><PARAM NAME="wmode" VALUE="transparent"><PARAM NAME="allowScriptAccess" VALUE="always"><PARAM NAME="allowFullScreen" VALUE="true"><a href="http://www.multivu.com/players/English/7298631-sanofi-regeneron-pharmaceuticals-announce-positive-results-alirocumab-trials-at-esc-congress">Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014</a></OBJECT>